Focus: Pasithea Therapeutics is a Miami-based biotechnology company focused on mental health and brain disorders spanning neurology and psychiatry. The company operates at a mid-stage scale with 51-200 employees and maintains a portfolio of generic ANDAs alongside early-stage pipeline programs.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Pasithea Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic tetracycline antibiotic with broad-spectrum activity; pre-launch status suggests recent entry or formulation development.
Help build intelligence for Pasithea Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pasithea Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Mature corticosteroid post-loss of exclusivity; limited growth or differentiation potential in crowded generic market.
Vintage anxiolytic with CNS effects; relevant to company's mental health focus but outdated relative to modern psychiatry standards.
OTC-grade antihistamine; minimal strategic value and misaligned with specialty mental health positioning.
+6 more products
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub